Quantgene and CureMatch Announce Strategic Partnership To Help Cancer Patients Find the Best Precision Treatment
SANTA MONICA, Calif., March 24th, 2021 – Quantgene, Inc. and CureMatch, Inc. have announced a strategic partnership to combine genomic, cloud and AI technologies and improve precision treatments and long-term outcomes for patients diagnosed with cancer.
Quantgene Liquid uses blood samples of cancer patients to help provide a systemic understanding of the mutational profiles of a tumor, also known as a “Liquid Biopsy”. Liquid Biopsies allow physicians to understand the mutational status of tumors without being limited to just a biopsy from a specific part of the tumor. By profiling cell-free DNA fragments in the blood, Quantgene Liquid allows better insights into both primary and metastatic tumors. Quantgene Liquid’s technology is a highly accurate and precise cancer mutation detection system.
The CureMatch Decision Support System provides actionable intelligence to oncologists. CureMatch supports the doctor with therapy options matched….Read More